Crystalys Therapeutics
Crystalys Therapeutics raises $205M Series B at $900M valuation
Crystalys Therapeutics: Series B Funding Round
Crystalys Therapeutics has successfully raised $205M in Series B funding, reaching a valuation of $900M.
Company Overview
Developing novel therapeutics for neurodegenerative diseases
Funding Details
The Series B round was led by Fidelity, with participation from Viking Global.
Company Information
- Headquarters: Boston, MA
- Founded: 2021
- Employees: 110+
- Category: Biotech
Investment
Crystalys Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series B
- Viking Global: Verified investor in Series B
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started